Sugi Predict

Sugi Predict / Compounds / SCHEMBL1141

SCHEMBL1141

SCHEMBL1141

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCNCC4)ccc3OCC)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 18/20 1.00
▸ PDE3B Q13370 3/20 0.86
▸ PDE3A Q14432 3/20 0.86
▸ ABCC4 O15439 2/20 0.86
▸ PDE2A O00408 1/20 0.86
▸ ABCC5 O15440 1/20 0.86
▸ PDE6D O43924 1/20 0.86
▸ PDE8A O60658 1/20 0.86
▸ PDE9A O76083 1/20 0.86
▸ ABCB11 O95342 1/20 0.86
▸ CYP3A4 P08684 1/20 0.86
▸ HTR1A P08908 1/20 0.86
▸ PDE6A P16499 1/20 0.86
▸ PDE6G P18545 1/20 0.86
▸ PDE4A P27815 1/20 0.86
▸ ADORA2A P29274 1/20 0.86
▸ ADORA1 P30542 1/20 0.86
▸ ADRA1A P35348 1/20 0.86
▸ PDE6B P35913 1/20 0.86
▸ PDE6C P51160 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30199797 1.00 PDE5A (1.00) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL14836841 0.97 PDE5A (0.94) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL30848678 0.95 PDE5A (0.95) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL997 0.94 PDE5A (0.89) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL24430033 0.94 PDE5A (0.89) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL25118239 0.94 PDE5A (0.88) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL28415489 0.93 PDE5A (0.88) PDE5APDE3BPDE3AABCC4PDE2A
Sildenafil SCHEMBL5683880 0.93 PDE5A (1.00) PDE5APDE3BPDE3AABCC4PDE2A
Sildenafil SCHEMBL1895 0.93 PDE5A (1.00) PDE5APDE3BPDE3AABCC4PDE2A
Sildenafil SCHEMBL29361663 0.93 PDE5A (1.00) PDE5APDE3BPDE3AABCC4PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111297868-A Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases 黄泳华 2020-06-19 — — CN claimed
US-8716298-B2 Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (KR) 2014-05-06 — — US claimed
EP-2556820-A2 COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES SK Chemicals, Co., Ltd. (KR) 2013-02-13 — — EP claimed
US-20130030174-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2013-01-31 — — US claimed
US-20060014754-A1 Methods and compositions for treating diseases and conditions of the eye PFIZER INC. 2006-01-19 — — US claimed
US-20020119974-A1 Methods and compositions for treating diseases and conditions of the eye LATIES ALAN M (US) 2002-08-29 — — US claimed
US-6225315-B1 ADMINISTERING A CGMP PDE INHIBITOR. PFIZER INC 2001-05-01 — — US claimed
EP-1074258-A2 Methods and compositions for treating diseases and conditions of the eye Pfizer Products Inc. (US) 2001-02-07 — — EP claimed
EP-1022026-A2 Pharmaceutical compositions for treating nitrate-induced tolerance Pfizer Limited (GB) 2000-07-26 — — EP claimed
EP-0463756-B1 Pyrazolopyrimidinone antianginal agents PFIZER LTD (GB) 1995-04-19 — — EP claimed
US-5250534-A Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase PFIZER INC. (US) 1993-10-05 — — US claimed
EP-0463756-A1 Pyrazolopyrimidinone antianginal agents Pfizer Limited (GB) 1992-01-02 — — EP claimed
US-20230041334-A1 METHODS AND COMPOSITIONS FOR SMOKING CESSATION BEHAVIORAL DIAGNOSTICS, LLC (US) 2023-02-09 — — US disclosed
CN-113155992-B Method for simultaneously detecting concentration of aromatase inhibitor, phosphodiesterase type 5 inhibitor and metabolite of aromatase inhibitor in human plasma 金橄榄科技(上海)有限公司 2022-11-29 — — CN disclosed
CN-107847462-B Targeting cGMP-related phosphodiesterases to reduce cyst formation of cystic kidney disease and related materials and methods 美国印第安纳大学研究和技术公司 2021-08-10 — — CN disclosed
CN-113155992-A Method for simultaneously detecting concentration of aromatase inhibitor, phosphodiesterase type 5 inhibitor and metabolite of aromatase inhibitor in human plasma 上海容圣生命科技有限公司 2021-07-23 — — CN disclosed
EP-0463756-B1 Pyrazolopyrimidinone antianginal agents PFIZER LTD (GB) 1995-04-19 — — EP disclosed
US-5346901-A Treatment of angina, hypertension, heart failure and atherosclerosis PFIZER INC. (US) 1994-09-13 — — US disclosed
US-5250534-A Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase PFIZER INC. (US) 1993-10-05 — — US disclosed
EP-0463756-A1 Pyrazolopyrimidinone antianginal agents Pfizer Limited (GB) 1992-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119974-A1 Methods and compositions for treating diseases and conditions of the eye PDE6C, PDE6D, PDE5A PDE5A 3/4885PDE3B 8/4885PDE3A 6/4885
US-20230041334-A1 METHODS AND COMPOSITIONS FOR SMOKING CESSATION PDE5A, PDE3A, PDE2A PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885
US-20060014754-A1 Methods and compositions for treating diseases and conditions of the eye PDE6C, PDE6D, PDE6A PDE5A 5/4885PDE3B 9/4885PDE3A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.